Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

BACKGROUND: We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate. METHODS: In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history of COVID-19 disease were assigned to intramuscular injectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanhoutte, Frédéric, Liu, Wen, Wiedmann, Richard T., Haspeslagh, Liesbeth, Cao, Xin, Boundy, Keith, Aliprantis, Antonios, Davila, Michelle, Hartzel, Jonathan, Li, Jianing, McGuire, Mac, Ramsauer, Katrin, Tomberger, Yvonne, Tschismarov, Roland, Brown, Deborah D., Xu, Weifeng, Sachs, Jeffrey R., Russell, Kevin, Stoch, S. Aubrey, Lai, Eseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759950/
https://www.ncbi.nlm.nih.gov/pubmed/35042081
http://dx.doi.org/10.1016/j.ebiom.2021.103811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759950/
https://www.ncbi.nlm.nih.gov/pubmed/35042081
http://dx.doi.org/10.1016/j.ebiom.2021.103811

Ejemplares similares